Research article summary (published 30 Jul 2006):

Pharmacologic treatment for obesity. Options for today...and tomorrow.

Full Abstract

No abstract is currently available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Author information

Author/s: Lundquist, Lisa M (LM); Sirimaturos, Michael (M); Cannon, Erin (E);

Affiliation: Grady Health System, Atlanta, USA.

Journal and publication information

Publication Type: Journal Article; Review

Journal: Advance for nurse practitioners (Adv Nurse Pract), published in United States. (Language: eng)

Reference: 2006-Aug; vol 14 (issue 8) : pp 31-5, 64

Dates: Created 2006/09/15; Completed 2006/10/13; Revised 2007/11/15;

PMID: 16972485, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Anti-Obesity Agents - adverse effects; therapeutic use Clinical Trials as Topic Cyclobutanes - adverse effects; therapeutic use Drug Therapy, Combination Humans

Lactones - adverse effects; therapeutic use Obesity - drug therapy Piperidines - adverse effects; therapeutic use Pyrazoles - adverse effects; therapeutic use Weight Loss

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: Anti-Obesity Agents (0) ; Cyclobutanes (0) ; Lactones (0) ; Piperidines (0) ; Pyrazoles (0) ; sibutramine (106650-56-0) ; rimonabant (158681-13-1) ; orlistat (96829-58-2)

Related articles

These are the most related articles currently in our database:

• Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. 29 Sep 2007
• Drug treatments for obesity: orlistat, sibutramine, and rimonabant. 4 Jan 2007
• [Drug treatment of obesity] 7 Jan 2006
• [Pharmacotherapy of obesity] 29 Nov 2006
• [New therapeutic aspects for the control of risk factors in obesity] 5 Apr 2007
• Long-term pharmacotherapy for obesity and overweight. 30 Dec 2002
• The obesity pandemic--how did we get here? 22 Jul 2007
• Current and novel approaches to the drug therapy of obesity. 24 Aug 2006
• Drug treatment of the overweight patient. 29 Apr 2007
• NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. 30 Jul 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.